Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

 

Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
U

Preventing Relapse in MDS After alloTx: Relapse Remains Major Challenge After Tx, Novel Treatments May Compete w/ alloTx in Some Patients

By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Uwe Platzbecker
By Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019) FEATURING Uwe Platzbecker
0 views
November 19, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Featured Video

24:35
Indy Hematology Review

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Feat. A. Tefferi
Myelodysplastic Syndromes
13:27
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

New Therapeutic Strategies in MDS: Increased Role of Genomic Annotat…

Feat. G. Garcia-Manero
13:28
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Progress in Targeting the TGFb Pathway in MDS: TGF-Beta Inhibitors S…

Feat. A. Verma
13:12
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Managing TP53-Mutant MDS in 60 y/o Female w/ PMH of Stage 2 Breast A…

Feat. D. Sallman
15:31
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Is TELESTO Trial the Final Answer to Iron Chelation Therapy in MDS?

Feat. E. Angelucci
15:54
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

The Role of DNA Methyltransferase Inhibitors in the Modern Therapy o…

Feat. M. Savona
14:28
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Preventing Relapse in MDS After alloTx: Relapse Remains Major Challe…

Feat. U. Platzbecker
06:11
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Ring Sideroblast Quantification is Highly Predictive of TP53 Mutatio…

Feat. D. Swoboda
04:30
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)

Demographics and Survival in Atypical Chronic Myeloid Leukemia: SEER…

Feat. N. Anusim